Abivax Completes Enrollment in ABX464 Trial for Ulcerative Colitis
News, Ulcerative colitis
Abivax has completed patient enrollment, ahead of schedule and despite the COVID 19 pandemic, in its Phase 2b trial evaluating ABX464 as a treatment candidate for people with moderate-to-severe ulcerative ... Read more